A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes
The DOI matches its Crossref record.
Abstract
BACKGROUND: Evidence of the antidepressant efficacy of lamotrigine is increasing, although there are no placebo-controlled trials of lamotrigine augmentation in depression. The aim of this study was to assess if augmentation with lamotrigine was superior to placebo in patients who were receiving fluoxetine for resistant major depressive episodes. METHOD: Twenty-three patients who had experienced at least 1 major depressive episode that was resistant to at least 1 prior trial of antidepressant therapy were selected. These patients were treated with fluoxetine, 20 mg/day, and concomitantly randomly assigned to receive either lamotrigine (N = 13) or placebo (N = 10) for 6 weeks. The dose of lamotrigine was titrated upward from 25 mg/day to 100 mg/day. Patients suffering from bipolar II disorder (N = 8) or from major depressive disorder (N = 15) (DSM-IV criteria) were enrolled, resulting in heterogeneity of the sample. The primary outcome measure was Hamilton Rating Scale for Depression score. Data were collected from 2000-2001. RESULTS: Lamotrigine was statistically superior to placebo on the Clinical Global Impressions scale at endpoint, both in absolute terms (mean +/- SD Clinical Global Impressions-Severity of Illness scores: lamotrigine, 2.15 +/- 1.28; placebo, 3.40 +/- 1.17; p =.0308) and using a responder analysis, with response defined as a Clinical Global Impressions-Improvement score of 2 or less (lamotrigine, 84.62% [N = 11]; placebo, 30.00% [N = 3]; p =.013). The effect of lamotrigine on Clinical Global Impressions scale scores was seen in both major depressive disorder and bipolar II disorder. Lamotrigine, however, failed to separate statistically from placebo on the Hamilton Rating Scale for Depression and Montgomery-Asberg Depression Rating Scale. This failure to differentiate on a primary outcome measure is essentially a negative study result. This result is most likely an artifact of the small sample size used and the resultant limited power of the study. CONCLUSION: The results of this trial add to the literature suggesting potential efficacy of the antidepressant profile of lamotrigine. In addition, this study points to a possible role of lamotrigine as an augmentation agent in depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two studies (Barbosa et al., 2003; Carpenter et al., 2002) had included patients with MDD (n=38) and bipolar-II disorder (n=11), without providing separate outcomes for MDD patients.”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Barbosa et al., 2003
Citations
Cited by
Items 101–163 of 163
Successful rechallenge with slowly titrated lamotrigine after rash
Manfredi, G., Pacchiarotti, I., Kotzalidis, G. D., Ruberto, A., Girardi, P., & Tatarelli, R. (2004) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00106.x · Cited by 11
The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression
Šagud, M., Pivac, N., Mustapić, M., Erjavec, G. N., Peleš, A. M., Kramarić, M., Jakovljević, M., & Mück‐Šeler, D. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1074-2 · Cited by 10
“The antidepressant effect of lamotrigine (present study) is in line with data showing that lamotrigine, as an augmentation therapy in depression, accelerated the onset of action of paroxetine (Normann et al. 2002) and fluoxetine ( Barbosa et al. 2003 ).”
ResultIntroducing the Term “Neuroregulator” in Psychiatry
Binder, M. R. (2019) · American Journal of Clinical and Experimental Medicine · doi:10.11648/j.ajcem.20190703.11 · Cited by 10
“Moreover, what in some studies has been diagnosed as unipolar depression has demonstrated responsiveness to anticonvulsants in both augmentation [33, 34] and single-agent protocols [4, 35].”
BackgroundDETERMINATION OF LAMOTRIGINE IN TABLETS USING HPTLC, HPLC, AND DERIVATIVE SPECTROPHOTOMETRY METHODS
Koba, M., Marszałł, M. P., Sroka, W. D., Tłuchowska, M., & Bączek, T. (2013) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2012.668735 · Cited by 9
“Other studies recommend lamotrigine for treatment of peripheral neuropathy, trigeminal neuralgia, cluster headaches, migraines, and reducing neuropathic pain or for used in adjunctive therapy for treatment of refractory unipolar depression.([7]) However, its overdose leads to uncontrolled seizures in most patients.”
BackgroundNew Uses for Lithium and Anticonvulsants
Salzman, C. (2003) · Harvard Review of Psychiatry · doi:10.1080/hrp.11.5.230.244 · Cited by 10
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
Treatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 9
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
Saddar, E., El‐Tawoosy, M., & Motaleb, H. A. (2014) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-014-3139-5 · Cited by 7
Lithium, Thyroid Hormones and Further Augmentation Strategies in Treatment‐resistant Depression
Haußmann, R., & Bauer, M. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch6 · Cited by 7
The Care of Patients With Complex Mood Disorders
Cordner, Z. A., MacKinnon, D. F., & DePaulo, J. R. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200007 · Cited by 6
Dépression résistante : les stratégies de potentialisation
Doumy, O., Bennabi, D., El‐Hage, W., Allaïli, N., Bation, R., Bellivier, F., Holtzmann, J., Bubrovszky, M., Camus, V., Charpeaud, T., et al. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.02.004 · Cited by 11
Arnone, D., Östlundh, L., Mosa, M., MacDonald, B., Oldershaw, J., Qassem, T., & Young, A. H. (2025) · Pharmaceuticals · doi:10.3390/ph18101590 · Cited by 7
“Three studies evaluated lamotrigine vs. placebo as an additional treatment to selective serotonin reuptake inhibitors (SSRIs) fluoxetine [46] and paroxetine [47,48].”
Drug Class Review: Antiepileptic Drugs for Indications Other Than Epilepsy
McDonagh, M. S., Peterson, K., Lee, N., & Thakurta, S. (2008) · Cited by 7
Polypharmazie in der Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_1 · Cited by 5
An Evidence-Based Approach to the Management of Depression
Maurer, D., & Colt, R. (2006) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2006.09.003 · Cited by 6
(2005) · CRC Press eBooks · doi:10.1201/b14455-5 · Cited by 5
Treatment resistant depression: Challenges and therapeutic choices
Touloumis, C. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.047 · Cited by 4
Fredskild, M. U., Bruun, C. F., Vinberg, M., Faurholt‐Jepsen, M., Kessing, L. V., & Munkholm, K. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.125 · Cited by 7
Hussain, A., Shah, M. S., Roub, F. E., Dar, M. A., Wani, Z. A., Jan, M. M., Wani, R. A., & Bhat, T. A. (2015) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.162916 · Cited by 3
“Limited data is available suggesting efficacy of Lamotrigine in major depressive disorder (MDD) (unipolar depression) and these studies do not support Lamotrigine use in unipolar depression robustly.[33,34]”
BackgroundPharmakologische Behandlungsmöglichkeiten bei therapieresistenter Depression
Kahl, K. G. (2012) · Nervenheilkunde · doi:10.1055/s-0038-1628182 · Cited by 4
Santos, M. A., Hara, C., Stumpf, B. P., & Rocha, F. L. (2006) · Jornal Brasileiro de Psiquiatria · doi:10.1590/s0047-20852006000300010 · Cited by 9
Depression: An Update for the Clinician
Nierenberg, A. A., Eidelman, P., Wu, Y. P., & Joseph, M. (2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.3 · Cited by 3
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · doi:10.3109/9781420084887-5 · Cited by 4
Evidence-based pharmacotherapy of major depressive disorder
Dupuy, J. M., Ostacher, M. J., Huffman, J. C., Perlis, R. H., & Nierenberg, A. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.005 · Cited by 4
Treatment of Refractory Depression
Gitlin, M. J. (2005) · Wiley eBooks · doi:10.1002/9783527619672.ch15 · Cited by 3
Glutamate-Modulating Drugs & the Treatment of Mental Disorders
Howland, R. H. (2007) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20070101-04 · Cited by 3
Where Does Lamotrigine Fit in the Pharmacotherapy of Mood Disorders? An Evidence-Based Appraisal
Goldberg, J. F. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23ac15219 · Cited by 2
“24 However, a subsequent larger (n = 96) 10-week multisite trial of lamotrigine or placebo in major depression unresponsive to paroxetine and 1 prior antidepressant showed no advantage over placebo on any depression symptom severity scales, clinical global impression scores, or functional outcome…”
BackgroundThe Use and Side Effect Profile of Valproate and Lamotrigine in Child and Adolescent Psychiatry
Sağlam, Y., TURAN, K., Şükret, A. L. E. V., & Karaçetin, G. (2025) · Namık Kemal Tıp Dergisi · doi:10.4274/nkmj.galenos.2025.80958 · Cited by 2
“In the study evaluating lamotrigine as augmentation in patients with treatment-resistant MDD receiving fluoxetine treatment, the effect of lamotrigine on Clinical Global Impression scores was found to be significant both in MDD and bipolar disorder 18 .”
Lamotrigine for bipolar disorder: translating research into clinical practice
Fung, J., Mok, H., & Yatham, L. N. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.3.363 · Cited by 2
Kolshus, E., Douglas, L., & Dunne, R. A. (2011) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700011800 · Cited by 3
Howland, R. H., & Thase, M. E. (2005) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615377350.lg07 · Cited by 7
Pharmacological Management of Treatment‐Resistant Unipolar Depression
McGrath, P. J., & Miller, J. M. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch112 · Cited by 2
Pharmacological Profile and Clinical Utility of Lamotrigine in Mood Disorders
van der Loos, M. L. M., Calabrese, J. R., Nolen, W. A., & Muzina, D. J. (2011) · Wiley eBooks · doi:10.1002/9780470975114.ch4 · Cited by 2
Goldberg, J. F. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00047.x · Cited by 1
“Similarly, despite encouraging preliminary open label data, three placebo-controlled studies have failed to demonstrate efficacy for adjunctive lamotrigine in treatment-resistant unipolar depression (3-5).”
ResultKombinasjonsbehandling ved depresjon
Høiseth, G., Solberg, D. K., & Refsum, H. (2012) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.11.1250 · Cited by 1
“Kombinasjon av et SSRI-middel med et stemningsstabiliserende legemiddel, for eksempel lamotrigin, er i enkelte studier vist å ha effekt (9).”
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · Medical psychiatry · doi:10.3109/9781420084887.003 · Cited by 2
Biological treatments of depression and anxiety
McGuffin, P., & FARMER, A. E. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544125.028 · Cited by 1
Combined treatments for major depression
Joffe, R. T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1379 · Cited by 1
“In a recent controlled trial in a small number of subjects, lamotrigine was superior to placebo in augmenting fluoxetine response in 23 subjects with major depression [120] .”
BackgroundTackling Partial Response to Depression Treatment
Thase, M. E., Gaynes, B. N., Papakostas, G. I., Shelton, R. C., & Trivedi, M. H. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.8133ah3c · Cited by 3
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.004
Major Depression and Metabolic Encephalopathy: Syndromes More Alike Than Not?
Harvey, B. H. (2008) · Springer eBooks · doi:10.1007/978-0-387-79112-8_18
El papel de los eutimizantes en la profilaxis de recaídas y recurrencias de la depresión
Ruiz, J. S., & Rodríguez, J. M. M. (2004) · Psiquiatría Biológica
Pae, C.-U., Han, C., Marks, D. M., & Patkar, A. A. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.10.012
EFEITO ANTIDEPRESSIVO DA LAMOTRIGINA NO MODELO DE NATAÇÃO FORÇADA MODIFICADO EM RATOS
Consoni, F. T. (2005) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Luchini, F., Cosentino, L., Pensabene, L., Mauri, M., & Lattanzi, L. (2015)
Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_1
Role of Antiepileptic Drugs in the Treatment ofMajor Depressive Disorder
Nelson, E. B. (2008) · Medical psychiatry · doi:10.3109/9780849382666.010
Serafini, G., Hayley, S. P., Ghasemi, M., & Amore, M. (2017) · Wiley eBooks · doi:10.1002/9783527803781.ch11
Shim, S. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-6173
Diah, P. P., & Buanasari, B. (2019) · Parapemikir Jurnal Ilmiah Farmasi · doi:10.30591/pjif.v8i2.1469 · Cited by 1
“Pasien depresi sering diberikan terapi antipsikotik untuk meningkatkan efek antidepresan dan mencegah terjadinya mania ([3]).”
BackgroundMcLaughlin, P., & Cleare, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.009
Bharath, R. S., Aswini, A., Arshiya, J., Yadav, J. N., Siddartha, G., & Paul Richards, M. (2017) · International Journal of Pharmacy
Current Treatments for Depression
Krystal, J. H., & Charney, D. S. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0031
Seemüller, F., & Grunze, H. (2005) · Springer eBooks · doi:10.1007/3-540-28049-9_21
Kalra, H., Dean, O. M., Dodd, S., & Berk, M. (2012) · doi:10.2217/ebo.11.273
Self-citationBrennan, B. P., & Pope, H. G. (2012) · doi:10.1093/med/9780199696758.003.0156
Hierarchical and Complex Pharmacotherapy Decision-Making
Goldberg, J. F., & Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009181549.011
Drug and Physical Treatments of Depression
Williams, R. C., & Cleare, A. J. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.006 · Cited by 2
Prioritizing the Components of Any Decision-Making Model
Goldberg, J. F., & Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009181549.012
Sáiz, P. A., Saiz-González, D., & Sánchez, D. D. L. V. (2011) · Debates em Psiquiatria · doi:10.25118/2763-9037.2011.v1.875
Metadata
- Authors
- Barbosa, L., Berk, M., & Vorster, M.
- Affiliations
- University of the Witwatersrand (ZA)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-04-15
- Volume
- 64
- Issue
- 4
- Pages
- 403-407
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2064478935
- Cited by
- 165
- References
- 0
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 9 · 2014: 11 · 2013: 6 · 2012: 11
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Deakin Research Online (Deakin University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- lamotrigine, fluoxetine, antidepressant augmentation, treatment-resistant depression, major depressive disorder, bipolar II disorder, antidepressant efficacy, Clinical Global Impression Scale, Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, small sample size limitations, responder analysis, dose titration, adverse events, drug discontinuation
- MeSH terms
- Lamotrigine, Adolescent, Adult, Aged, Anticonvulsants, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Research Design, Severity of Illness Index, Triazines, Placebo Effect, Treatment Outcome, Outcome Assessment, Health Care, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.